CCPA Slaps Rs 10 Lakh Fine On Firm Selling Ayurvedic Oil Through ‘Misleading’ Advertisements

NEW DELHI: Continuing its crackdown on misleading advertisements, Central Consumer Protection Authority (CCPA) has imposed Rs 10 lakh fine on a company selling an ayurvedic product claiming it as “magic oil” which when applied makes one “fit even without any surgery or physiotherapy.”

The CCPA headed by Union consumer affairs secretary Nidhi Khare has ordered discontinuation of the misleading advertisement related to the product “Dhuandhar Oil ” manufactured by Indiyaa Distribution Network LLP. Officials said that during the process of investigation and hearing, the company could not substantiate any of the claims.

“The decision to impose fine and immediate discontinuation of advertisement was taken to protect and promote the rights of consumers as a class and ensure that no false or misleading advertisement is made for any goods or services, which contravenes the provisions of the Consumer Protection Act,” said an official.

The advertisement of the product was being telecast on the Arogya Rahasya Programme and on company’s website related to the product wherein they made several claims, which included describing the product as the “world’s 1st hotstream joint pain relieving oil” and “mere application of the oil gives patients quick relief from joint pain, stiffness, and inflammation,” and that the oil ensures fitness without surgery or physiotherapy.

It also claimed that the product is manufactured as per government rules and regulations and that regular application provides permanent relief from pain. The company also claimed that it has no side effects and no parallel product worldwide. “The advertisement mentioned a money-back guarantee and a person purported to be a doctor, wearing a white coat, also recommended the use of this oil to his patients for pain relief,” said the official.

Before passing the order, CCPA sent the matter to the director general of investigation which observed that in the absence of any supporting documents, research papers or scientific studies, the claim of the company appeared to be grossly exaggerated and misleading. “The company in its reply to CCPA submitted that players also use this product to keep themselves fit. However, during the investigation the company did not submit any evidence for its claims,” a source said.

Related Posts

Fire disrupts production at GSK Pharma’s contract manufacturing site

GlaxoSmithKline Pharmaceuticals (GSK Pharma) on Friday informed the stock exchanges that a fire had occurred at one of its contract manufacturing facilities, causing a temporary disruption in production at the…

  • Pharma
  • May 16, 2025
  • 103 views
Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

US President Donald Trump’s move to slash prescription drug prices by tying them to rates in countries such as the UK and Germany may rattle multinational pharmaceutical giants, but it…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Fire disrupts production at GSK Pharma’s contract manufacturing site

Fire disrupts production at GSK Pharma’s contract manufacturing site

Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

DCA seizes syrup stocks over misleading fever cure claim

DCA seizes syrup stocks over misleading fever cure claim

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Piramal Pharma stock falls 5% after Q4 results; check key numbers here

Piramal Pharma stock falls 5% after Q4 results; check key numbers here